Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Biotechnology
Photys Therapeutics launches with $75 million for phosphorylation-inducing molecules
by Gina Vitale
September 16, 2022
| A version of this story appeared in
Volume 100, Issue 33
Photys Therapeutics has debuted with $75 million in series A financing to develop phosphorylation-inducing chimeric small molecules (PHICs) to treat disease. PHICs are two-ended molecules that draw together kinases with proteins that are implicated in disease; the kinases phosphorylate the target proteins to modulate their function. The start-up was cofounded by Amit Choudhary of Brigham and Women’s Hospital and the Broad Institute of MIT and Harvard.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X